AiCure

Global News

AstraZeneca has acquired Almirall’s respiratory business

Wednesday, November 5, 2014 12:45 PM

Almirall, a global company based in Barcelona dedicated to providing valuable medicines through its R&D, agreements and alliances, has completed the transaction to transfer to AstraZeneca the rights to Almirall's respiratory franchise after all closing conditions have been satisfied. AZ now will own the rights for the development and commercialization of Almirall's existing proprietary respiratory business, including rights to revenues from Almirall's partnerships, as well as its pipeline of investigational novel therapies.

More... »


PDR, LDM Group merge

Wednesday, November 5, 2014 12:42 PM

PDR Network, a Montvale, N.J.-based provider of drug information and prescriber communications, has merged with LDM Group, a St. Louis, Mo.-based provider of behavior-based patient and consumer health information.  

More... »


AstraZeneca, Pharmacyclics, Janssen partner

Wednesday, November 5, 2014 12:37 PM

AstraZenecaPharmacyclics and Janssen R&D have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with imbruvica (ibrutinib), an oral Bruton's tyrosine kinase inhibitor, co-developed and co-commercialized by Pharmacyclics and Janssen Biotech. The study will assess the combination as a treatment for patients with hematologic cancers including diffuse large B-cell lymphoma and follicular lymphoma, which are investigational uses for both compounds.

More... »

Cleveland Clinic unveils Top 10 Medical Innovations for 2015

Monday, November 3, 2014 02:41 PM

Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education, has announced its 9th annual list of Top 10 Medical Innovations likely to have major impact on improving patient care in 2015. The list of up-and-coming technologies and drug therapies was selected by a panel of 110 Cleveland Clinic physicians and scientists. The Top 10 Medical Innovations for 2015 are:

More... »

Novartis to sell influenza vaccines business to CSL for $275M

Monday, November 3, 2014 02:39 PM

Novartis has agreed to divest its influenza vaccines business to CSL for $275 million. This transaction requires regulatory approvals and is expected to close in the second half of 2015.

More... »

Chiltern launches rebranding

Monday, November 3, 2014 02:37 PM

U.K.-based Chiltern has rebranded as a completely integrated and unified CRO with services that are "Designed Around You.”

More... »

Celerion expands lab capabilities for cell-based assay demand

Monday, November 3, 2014 02:36 PM

Celerion, a Lincoln, Neb.-based provider of early clinical research, has expanded laboratory capabilities to meet growing demand for cell-based assays. Assays involving whole cells provide a variety of measures of drug activity or effect that can be important endpoints in clinical research.

More... »

Clinical Network Services partners with Biologics Development Consultancy

Monday, November 3, 2014 02:34 PM

Clinical Network Services (CNS), an Australian, New Zealand and U.K. CRO focused on virtual, small and medium-sized biotech companies, and Biologics Development Consultancy (BDC), a Netherlands-based team of consultants providing regulatory and product development advice on development and commercial production, have signed a cooperative partnership agreement. CNS, and in particular the BioDesk consultancy, and BDC will mutually expand the expertise they can offer their clients.

More... »

Impax to reorganize R&D, cut 49 jobs

Monday, November 3, 2014 02:32 PM

Impax Laboratories, a Hayward, Calif.-headquartered, technology-based specialty pharmaceutical company, is cutting about a quarter of its R&D work force—42 of a total of 49 job cuts—as part of an R&D reorganization and prioritization of project portfolios within the generic and brand businesses.

More... »

Certara updates PK/PD Phoenix Platform

Monday, November 3, 2014 02:28 PM

Certara, a Princeton, N.J.-based global technology-enabled drug development and drug safety consultancy, has launched version 1.4 of its Phoenix product family.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs